Journal: Cancer Medicine

Article Title: SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR‐23b‐3p via sponging EGR1 in hepatocellular carcinoma

doi: 10.1002/cam4.3020

Figure Lengend Snippet: The lncRNA microarray data from Hep3B and Hep3B/So cells

Article Snippet: Human LncRNA Microaray V1.0 (Arraystar) was used to analyze the data of five replicate samples, calculate the p ‐value of the gene expression difference and statistical significance, and use the Fold Change (FC) ≥1.5 or ≤−1.5, P < .05 for t test as a criterion for differential gene screening.

Techniques: Microarray

Journal: Nature Communications

Article Title: circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity

doi: 10.1038/s41467-020-20527-z

Figure Lengend Snippet: a A heatmap and volcano plot show 109 differentially expressed circRNAs in three paired samples of NSCLC by Arraystar Human Circular RNA Microarray. Cut off is Log 2 (fold change) > 1 or <−1.0, P value < 0.05. b Analysis for RNA levels of circNDUFB2 in additional 52 paired samples of NSCLC (left). Expression proportions of circNDUFB2 in histogram and pie chart (right). Log 2 (T/N expression) value > 1 as significantly higher expression, which <−1 as significantly lower expression, and between −1 and 1 as no significant change. N nontumorous tissue, T tumorous tissue. Data are presented as mean ± s.d. P values are calculated by paired two-sided t -test. n = 52 biologically independent paired tissues of NSCLC. c The backsplice junction site of circNDUFB2 was identified by Sanger sequencing. d PCR analysis for circNDUFB2 and β-actin in cDNA and genomic DNA. RH random hexamers, OdT oligo(dT) 18 primers, gDNA genomic DNA. Two independent experiments were carried out with similar results. e Analysis for RNA levels of circNDUFB2 and NDUFB2 after treatment with RNase R. n = 3 biologically independent samples. f Analysis for RNA abundance of circNDUFB2 and NDUFB2 treated with Actinomycin D (2 μg/ml) at the indicated time point. n = 3 biologically independent samples. g RNA levels of circNDUFB2 , NDUFB2 , β-actin , and U1 in the nuclear and cytoplasmic fractions of A549 and H1650 cells. n = 3 biologically independent samples. h RNA FISH analysis for circNDUFB2 in A549 cells, scale bar = 15 μm. Two independent experiments were carried out with similar results. Data are presented as mean ± s.d in e – g . P values are calculated by unpaired two-sided t -test in a , e – g .

Article Snippet: The labeled cRNAs were hybridized onto the Arraystar Human Circular RNA Microarray V1.0 (6x7K, Arraystar), which contains 5396 probes specific for human circular RNAs backsplice junction region.

Techniques: Microarray, Expressing, Sequencing

Journal: Frontiers in Immunology

Article Title: Applications of Protein Microarrays in Biomarker Discovery for Autoimmune Diseases

doi: 10.3389/fimmu.2021.645632

Figure Lengend Snippet: Major protein microarray platforms for biomarker discovery in autoimmune diseases.

Article Snippet: The HuProtTM Human Proteome Microarray V1.0 was designed by Zhu lab at Johns Hopkins School of Medicine and produced by CDI Laboratories around 2012, containing 16,368 recombinant GST-His-tagged human proteins expressed in S. cerevisiae , and the current v4.0 contains more than 21,000 unique proteins.

Techniques: Microarray, Biomarker Discovery, Protein Array, Recombinant, In Silico, Selection, In Situ, Peptide Microarray, Ab Array, Bioprocessing

Journal: Frontiers in Immunology

Article Title: Applications of Protein Microarrays in Biomarker Discovery for Autoimmune Diseases

doi: 10.3389/fimmu.2021.645632

Figure Lengend Snippet: Selective application of protein microarrays in biomarker discovery for autoimmune diseases.

Article Snippet: The HuProtTM Human Proteome Microarray V1.0 was designed by Zhu lab at Johns Hopkins School of Medicine and produced by CDI Laboratories around 2012, containing 16,368 recombinant GST-His-tagged human proteins expressed in S. cerevisiae , and the current v4.0 contains more than 21,000 unique proteins.

Techniques: Biomarker Discovery, Enzyme-linked Immunosorbent Assay, Western Blot, Microarray, Immunopeptidomics, Protein Array, Diagnostic Assay, Recombinant, Purification, Derivative Assay, Competitive ELISA, Peptide Microarray, Software, Construct, Bioprocessing, Ab Array, Clinical Proteomics, Expressing, Amplified Luminescent Proximity Homogenous Assay, Multiplex Assay, Glycoproteomics, Membrane, Sequencing, Immunofluorescence, Staining, Virus, Immunohistochemistry, cDNA Library Assay, Clone Assay, Suspension, Apoptosis Assay, Stripping Membranes, In Silico, Activity Assay, Cytokine Assay